Immunic’s (IMUX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Immunic (NASDAQ:IMUX) in a research note released on Wednesday,Benzinga reports. The brokerage currently has a $17.00 price objective on the stock.

A number of other research analysts have also recently weighed in on IMUX. William Blair initiated coverage on shares of Immunic in a research note on Tuesday, March 25th. They issued an “outperform” rating on the stock. B. Riley reissued a “buy” rating and issued a $6.00 price target on shares of Immunic in a research report on Wednesday, April 16th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Immunic in a report on Tuesday, April 15th. Finally, StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $13.20.

Immunic Price Performance

Shares of IMUX stock opened at $1.15 on Wednesday. Immunic has a one year low of $0.83 and a one year high of $2.11. The company has a market cap of $110.19 million, a P/E ratio of -0.93 and a beta of 1.91. The firm has a 50-day moving average of $1.08 and a 200-day moving average of $1.11.

Institutional Investors Weigh In On Immunic

Institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. bought a new stake in shares of Immunic in the 4th quarter worth approximately $37,000. Virtu Financial LLC bought a new position in Immunic during the 3rd quarter valued at approximately $50,000. HB Wealth Management LLC purchased a new stake in shares of Immunic in the 4th quarter worth about $81,000. Barclays PLC purchased a new position in Immunic during the fourth quarter valued at $84,000. Finally, Jane Street Group LLC raised its stake in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the last quarter. 51.82% of the stock is owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.